October 27, 2025

Get Ready for CPHI: Off-Patent Semaglutide and Sustainability in a Shifting World

It’s showtime in Frankfurt – with around 62,000 attendees expected.

The Medicine Maker

October 24, 2025

Synbiotic Supplement Reduced Multiple Inflammatory Proteins

Butyrate rise corresponded with lower IL-6 during 6-week synbiotic supplementation.

Conexiant

October 24, 2025

A New Approach to Lowering Cardiovascular Risk?

Researchers evaluated obicetrapib’s effects on lipid levels and cardiovascular outcomes.

Conexiant

October 23, 2025

Waist Loss Only Part of Semaglutide’s Power

Semaglutide lowered cardiovascular events in patients with overweight or obesity without diabetes, independent of weight loss.

Conexiant

October 23, 2025

Sex-Stratified Genome Analysis Maps Depression Variants

X-chromosome variant and higher heritability distinguish male and female depression genetics.

Conexiant

October 22, 2025

Primary Care Workload: 62 Hours Weekly

Electronic records detail physician work hours across multiple primary care clinics.

Conexiant

October 22, 2025

Do GLP-1RAs Differ in Cardiometabolic Protection?

Researchers found that liraglutide and semaglutide offer similar cardiovascular and kidney benefits in type 2 diabetes.

Conexiant

October 22, 2025

Tariffs, Talent, and Technology: Inside Pharma’s Executive Recruitment Landscape

As tariffs and geopolitical uncertainty continue to disrupt supply chains, a new kind of biotech and pharma executive is emerging.

The Medicine Maker

October 21, 2025

UCI Health takes national lead in combating diabetes epidemic

With diabetes rates soaring, UCI Health launches a bold initiative to improve care, reduce disparities, and protect vulnerable communities.

UCI Health